Jonathan Yen-Wen Yu Sells 1,610 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 1,610 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the transaction, the chief operating officer now owns 40,555 shares in the company, valued at $2,213,491.90. This represents a 3.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Disc Medicine Stock Performance

Disc Medicine stock opened at $54.52 on Friday. The company has a 50 day moving average price of $59.05 and a 200 day moving average price of $55.19. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -13.70 and a beta of 0.73.

Analyst Upgrades and Downgrades

IRON has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. Scotiabank lifted their price target on shares of Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, January 22nd. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research report on Tuesday, November 5th. Finally, Stifel Nicolaus lifted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $88.90.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Sterling Capital Management LLC boosted its stake in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after purchasing an additional 503 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine during the 4th quarter valued at $40,000. Tower Research Capital LLC TRC boosted its stake in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after buying an additional 266 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares during the period. Finally, Quest Partners LLC acquired a new stake in shares of Disc Medicine during the 3rd quarter valued at $131,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.